Skip to main content

Automatic Labs succumbs to COVID-19, will soon shut down connected car service

Automatic Labs, a manufacturer of adapters that can transform vehicles into connected cars, will soon shut down, as the COVID-19 pandemic claims another corporate casualty.

The outbreak of the coronavirus has affected most industries, and Automatic is no exception. On its official website, the company said that the pandemic has “adversely impacted” its operations, as the outbreak is reshaping how Americans think about transportation

Recommended Videos

“With fewer consumers purchasing and leasing vehicles and drivers on the road, we, unfortunately, do not see a path forward for our business,” Automatic said.

Please enable Javascript to view this content

“These are unprecedented times, and with so much uncertainty ahead, we have made the difficult decision to discontinue the Automatic connected car product, service, and platform.”

Automatic will shut down operations on May 28, 11:59 p.m. PT, at which time all services offered by the company will abruptly end, including the Crash Alert and Real-Time Location & Sharing features. However, as a small consolation, there will be no degradation of Automatic’s services and features until the planned shutdown.

People who purchased Automatic hardware and services before April 30 may be eligible for a rebate, though Rebate Request Forms will have to be submitted by June 15. In addition, people requesting rebates will need to have made the purchase themselves, instead of receiving the products as part of a car deal.

Automatic, which offers adapters that can plug into the OBD ports of vehicles to gather and send data to its app,  was purchased by SiriusXM in 2017 for more than $100 million. With the pandemic having lasted only a few months, it appears that the company was already struggling even before the outbreak. This may be because auto insurance companies have rolled out devices similar to Automatic’s adapter, and many of the newer models of vehicles already come with the features enabled by Automatic, according to 9to5Mac.

Automatic follows Maven

The planned shutdown of Automatic follows the closure of another car-related company, General Motors’ carsharing service Maven, due to the coronavirus pandemic. Signs that the app-based service was in trouble started last year when it pulled out of eight of the 17 North American cities where it operated, and now, it is winding down its business, with the coronavirus outbreak proving to be the final straw.

Aaron Mamiit
Aaron received an NES and a copy of Super Mario Bros. for Christmas when he was four years old, and he has been fascinated…
The FDA has shut down a Bill Gates-backed coronavirus testing program
Bill Gates

The Food and Drug Administration (FDA) halted, at least temporarily, a Seattle-based at-home coronavirus testing program backed by Bill Gates.

“Please discontinue patient testing and return of diagnostic results to patients until proper authorization is obtained,” the FDA told the Seattle Coronavirus Assessment Network (SCAN) in a memo, according to The New York Times.

Read more
Fitbit is looking to make ventilators for COVID-19 patients
Four styles of Fitbit Charge 4

Wearable device maker Fitbit is looking to join the list of companies that are making ventilators to be used on people infected with COVID-19, the disease caused by the novel coronavirus.

Fitbit is soon submitting its technology to the Food and Drug Administration, for the ventilators to gain approval to be used specifically for COVID-19 patients, CEO James Park told CNBC.

Read more
Remdesivir: What to know about the ‘most promising’ COVID-19 treatment
Remdesivir vial

As scientists race to develop vaccines and treatments for COVID-19, there's one drug that's been getting a lot of attention: remdesivir. The Food and Drug Administration (FDA) has granted emergency use authorization to use it to treat the new virus.

Developed by pharmaceutical giant Gilead Sciences, remdesivir is an antiviral drug that was originally meant to fight the Ebola virus after an outbreak struck in 2013, but it was so ineffective that it was eventually shelved. However, despite its initial failures, remdesivir was later shown to be effective against both SARS and MERS, and is now being tested in new clinical trials as a potential treatment against COVID-19.

Read more